. Author manuscript; available in PMC: 2015 Oct 1.

Published in final edited form as: J Clin Pharm Ther. 2014 May 14;39(5):457–467. doi: 10.1111/jcpt.12171

Table 1.

Placebo-controlled clinical trials examining tobacco product abstinence rates from varenicline and bupropion SR treatments

Drug	Treatment regimen	Continuous abstinence or point prevalence rate (%)				Final N	Report
Drug	Treatment regimen	7 weeks	12 weeks	24 weeks	52 weeks	Final N	Report
Varenicline vs. Bupropion SR vs. Placebo
Varenicline	10 mg BID for 12 weeks	–	44.0^***^,^‡	29.5^***^,^†	21.9^***	352	Gonzales et al. 2006¹⁸⁸
Bupropion SR	150 mg BID for 12 weeks^a	–	29.5^***	20.7^***	161^***	352
Placebo		–	17.7	10.5	84	344
Varenicline	10 mg BID for 12 weeks	–	43.9^***^,^‡	29.7^***^,^†	23.0^***^,^†	344	Jorenby et al. 2006¹⁴⁰
Bupropion SR	150 mg BID for 12 weeks^a	–	29.8^***	20.2^**	14.6	342
Placebo		–	17.6	13.2	10.3	341
Varenicline	0.3 mg QD for 6 weeks	254^*	16.7	9.5	7.9	126	Nides et al. 2006¹⁵³
	1.0 mg QD for 6 weeks	31.0^**	15.1	9.5	5.6	126
	10 mg BID for 6 weeks	40.8^***	28.8^**	20.8^**	144^**	125
Bupropion SR	150 mg BID for 7 weeks	28.6^**	19.8^*	10.3	6.3	126
Placebo		13.8	10.6	7.3	4.9	123
Varenicline vs. Placebo
Varenicline	0.5 mg BID for 12 weeks	36.3^***	44.0^***	–	18.5^***^,^b	123	Oncken et al. 2006¹⁵⁴
Varenicline	10 mg BID for 12 weeks	39.8^***	49.4^***	–	22.4^***^,^b	146
Placebo		10.9	11.6	–	3.9^b	40
Varenicline	10 mg BID for 12 weeks^a	–	50.3^***	38.2^**	–	165	Wang et al. 2009¹⁹⁰
Placebo		–	31.6	25.0	–	168
Bupropion SR vs. Placebo
Bupropion SR	100 mg QD for 7 weeks	28.8^*	242^*	24.2	19.6	153	Hurt et al. 1997¹⁶⁵ ^b^,^c
	150 mg QD for 7 weeks	38.6^***	261^**	27.5^**	22.9^*	153
	300 mg QD for 7 weeks	44.2^***	29.5^***	26.9^*	23.1^**	156
Placebo		19.0	144	15.7	124	153
Bupropion SR	150 mg BID for 9 weeks^a	–	–	34.8^***	30.3^***	169	Jorenby et al. 1999¹⁶⁶ ^b
Placebo		–	–	18.8	15.6	82
Bupropion SR	150 mg BID for 7 weeks^a	46.0^***	32.0^e	25.0^***	21.0^***	527	Tønnesen et al. 2003¹⁸⁹ ^d
Placebo		23.0	18.0	13.0	110	180

Adapted from^{140,153,154, 165,166, 188–190}.

P ≤ .05 compared to placebo.

^**

P ≤ .01 compared to placebo.

^***

P ≤ .001 compared to placebo.

^†

P ≤ .01 compared to bupropion SR.

^‡

P ≤ .001 compared to bupropion SR.

Dose titration within first 7 days of treatment.

Point prevalence rate only at 52 weeks for¹⁵⁴ and at all time points for^165,166.

Time points for continued abstinence rate (CAR) findings are: 6 weeks, 3 months, 6 months and 12 months, respectively.

Time points for CAR findings are: 7 weeks, 12 weeks, 26 weeks and 52 weeks, respectively.

Statistics not performed.